Clinical trials: Inflammatory Bowel Disease 1
Crohn Disease
Adalimumab for the Management of Post-operative Crohn's Disease (CD)
This study will be a prospective, open label, randomized, comparative study. Comparing the efficacy of adalimumab with immunomodulator therapy (i.e.
- Trial name
- POPART (NCT01629628)
- Testing
- Adalimumab, 6 Mercaptopurine
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Inflammatory Bowel Diseases, Crohn Disease
Bowel Urgency in Inflammatory Bowel Disease
Bowel urgency is commonly defined as the sudden need to rush to the bathroom to empty one's bowel. In the field of inflammatory bowel disease (IBD) (including Crohn's disease (CD) and ulcerative colitis (UC)), bowel urgency is…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- URGENT-1 (NCT06069167)
- Testing
- Collection of data related to bowel urgency
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Paris IBD Center
Crohn Disease
Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason
The investigators plan to compare contrast-enhanced ultrasound to CT and MRI for the detection and quantification of intestinal inflammation in the the setting of pediatric small bowel Crohns disease
- Trial name
- NCT03492944
- Testing
- Ultrasound Microbubble Contrast Agent, Ultrasound Imaging
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Crohn Disease
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
The purpose of this study is to evaluate whether treatment with Leukine in patients with Crohn's disease who have previously responded to Leukine can be helped again, once they have relapsed.
- Trial name
- NCT00206713
- Testing
- Sargramostim (Leukine)
- Where
- 7 sites in United States
- Volunteers
- 264 people
- Sponsor
- Genzyme, a Sanofi Company
Crohns Disease
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
The study is being conducted to evaluate the pharmacokinetic parameters (Cmax, Tmax and AUC) of the new delayed release, lowered dose, 40 mg 6MP test formulation as compared to standard 6MP (100 mg Purinethol) in 12 patients with…
- Trial name
- NCT00774982
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Teva GTC
Pediatric Crohn's Disease
Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease
Crohn's disease (CD) is an incurable debilitating disorder affecting an increasing number of children. The etiology remains elusive, but a genetically determined aberrant immune response against microbiota appears to be…
- Trial name
- NCT01752790
- Testing
- Top-down, Step-up
- Where
- Italy
- Sponsor
- University of Roma La Sapienza
Inflammatory Bowel Diseases, Crohn Disease
Digestive Biobank for Exploring Microbiota-host Interactions
Constitution of a biobank of tissues, whole blood and plasma samples and stools to identify markers associated with treatment response, postoperative morbidity including neuro-cognitive and mood complications and prognosis of…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colorectal Cancer
- Trial name
- BiomHost (NCT05704413)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Crohn's Disease
Vagus Nerve Stimulation in Crohn's Disease
This is an open label interventional study using an implantable vagus nerve stimulation device in patients with Crohn's disease who have active disease despite treatment with a tumor necrosis factor (TNF) antagonist drug.
- Trial name
- NCT02311660
- Testing
- Vagus Nerve Stimulation Device
- Where
- 4 sites in Croatia, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- SetPoint Medical Corporation
Crohn's Disease, Ulcerative Colitis
Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
This study aims to test the hypothesis that the accelerated infusion of infliximab is not inferior to the conventional 2 hour infusion with respect to the frequency of infusion reaction.
- Trial name
- NCT01346826
- Testing
- Standard 2 hours-infusion, Accelerated 1 hour-infusion, Accelerated 30 minutes-infusion
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Asan Medical Center
Crohn Disease
Effects of Acupuncture on Abdominal Pain-related Intestinal Flora in Patients With Crohn's Disease
Crohn's disease is an intestinal inflammatory disease, causing abdominal pain, diarrhea and other symptoms. The intestinal flora disorder is closely related to the occurrence and development of Crohn's disease.
- Trial name
- NCT06375382
- Testing
- acupuncture
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Crohn Disease
Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study
To assess the safety and efficacy of transcutaneous vagal stimulation in adult patients with active Crohn's disease.
- Trial name
- VNS (NCT05165108)
- Testing
- Vagal Nerve Stimulator
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Crohn's Disease
Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
The purpose of this study is to measure the changes in small bowel uptake of radioligand [11^C]AZ14132516 after intravenous (IV) administration of single and repeat doses of AZD7798 in healthy participants and participants with…
- Trial name
- NCT06053424
- Testing
- AZD7798, [11C]AZ14132516
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Inflammatory Bowel Diseases, Crohn Disease
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNFα (infliximab, adalimumab or golimumab), vedolizumab, ustekinumab and tofacitinib will be made…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- BioIBD (NCT03885713)
- Testing
- Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
- Where
- 21 sites in Spain
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Ulcerative Colitis, Crohn's Disease
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to…
- Trial name
- NCT00619489
- Testing
- vedolizumab
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Inflammatory Bowel Disease, Crohn's Disease
The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel Disease
Background: Bacteria and other microorganisms that live in the intestines (the gut microbiome) play an important role in a person s health. The gut microbiome helps to regulate the immune system and control inflammation.
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT05652491
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Crohn Disease
Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel
The purpose of this study is to assess the exam quality and accuracy of MR using a new oral contrast agent for the evaluation of Crohn Disease in the small bowel.
- Trial name
- NCT00587210
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Colitis Ulcerative, Crohn Disease
Mesalamine and Reproductive Health Study
The purpose of this study is to investigate the relationship of high exposure to dibutyl phthalate (DBP) from the use of Asacol with clinical and intermediate markers of male fertility, including semen quality, sperm DNA damage…
- Trial name
- MARS (NCT01331551)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Harvard School of Public Health (HSPH)
Crohn's Disease, Inflammatory Bowel Disease
Dietary Treatment of Crohn's Disease
Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
- Trial name
- NCT00343642
- Testing
- Active fructo-oligosaccharide, Diet
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Rush University Medical Center
Ulcerative Colitis (UC), Crohn's Disease
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation…
- Trial name
- NCT04254783
- Testing
- Risankizumab, Cytochrome P450 (CYP) Substrates
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- AbbVie
Crohn's Disease
Safety of Celecoxib in Patients With Crohn's Disease
The investigators will select 60 people who are 18-70 years of age with Crohn's disease and randomly assign them to receive an 8-week trial of celecoxib and an 8-week trial of a placebo.
- Trial name
- NCT00177866
- Testing
- Celebrex
- Volunteers
- 28 people
- Sponsor
- University of Pittsburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.